BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
138.8 EUR
-3.95 (-2.77%)
Overall IDP gets a fundamental rating of 6 out of 10. We evaluated IDP against 86 industry peers in the Biotechnology industry. IDP gets an excellent profitability rating and is at the same time showing great financial health properties. IDP is valued quite cheap, but it does not seem to be growing. With these ratings, IDP could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
- IDP had positive earnings in the past year.
- IDP had a positive operating cash flow in the past year.
- IDP had positive earnings in each of the past 5 years.
- Each year in the past 5 years IDP had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 5.51%, IDP belongs to the top of the industry, outperforming 83.72% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 8.84%, IDP belongs to the top of the industry, outperforming 83.72% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 9.70%, IDP belongs to the best of the industry, outperforming 88.37% of the companies in the same industry.
- IDP had an Average Return On Invested Capital over the past 3 years of 10.57%. This is in line with the industry average of 11.58%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
- IDP has a better Profit Margin (15.98%) than 83.72% of its industry peers.
- In the last couple of years the Profit Margin of IDP has declined.
- IDP has a better Operating Margin (28.50%) than 87.21% of its industry peers.
- In the last couple of years the Operating Margin of IDP has declined.
- IDP has a Gross Margin of 75.24%. This is in the better half of the industry: IDP outperforms 68.60% of its industry peers.
- IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IDP is still creating some value.
- Compared to 1 year ago, IDP has more shares outstanding
- The number of shares outstanding for IDP has been reduced compared to 5 years ago.
- IDP has a better debt/assets ratio than last year.
2.2 Solvency
- IDP has an Altman-Z score of 3.18. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
- IDP's Altman-Z score of 3.18 is fine compared to the rest of the industry. IDP outperforms 72.09% of its industry peers.
- IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
- IDP's Debt to FCF ratio of 2.78 is amongst the best of the industry. IDP outperforms 84.88% of its industry peers.
- IDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
- IDP has a Debt to Equity ratio (0.35) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.18 |
ROIC/WACC1.16
WACC8.33%
2.3 Liquidity
- IDP has a Current Ratio of 2.72. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 2.72, IDP perfoms like the industry average, outperforming 58.14% of the companies in the same industry.
- A Quick Ratio of 2.04 indicates that IDP has no problem at all paying its short term obligations.
- With a Quick ratio value of 2.04, IDP perfoms like the industry average, outperforming 48.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 2.51% over the past year.
- Measured over the past years, IDP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
- IDP shows a small growth in Revenue. In the last year, the Revenue has grown by 4.77%.
- The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
- The Earnings Per Share is expected to grow by 0.59% on average over the next years.
- IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.63% yearly.
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.59%
Revenue Next Year1.93%
Revenue Next 2Y-1.65%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 9.65, the valuation of IDP can be described as reasonable.
- Compared to the rest of the industry, the Price/Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 96.51% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.38. IDP is valued rather cheaply when compared to this.
- With a Price/Forward Earnings ratio of 10.44, the valuation of IDP can be described as very reasonable.
- 97.67% of the companies in the same industry are more expensive than IDP, based on the Price/Forward Earnings ratio.
- IDP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.65 | ||
| Fwd PE | 10.44 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 94.19% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, IDP is valued cheaply inside the industry as 96.51% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.47 | ||
| EV/EBITDA | 7.13 |
4.3 Compensation for Growth
- The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
5. Dividend
5.1 Amount
- No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IDP (1/19/2026, 7:00:00 PM)
138.8
-3.95 (-2.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-06 2026-02-06/amc
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap20.36B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.33
Price Target163.18 (17.56%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)4.97%
PT rev (3m)10.15%
EPS NQ rev (1m)0.42%
EPS NQ rev (3m)-54.28%
EPS NY rev (1m)0.27%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-2.47%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)1.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.65 | ||
| Fwd PE | 10.44 | ||
| P/S | 2.35 | ||
| P/FCF | 10.47 | ||
| P/OCF | 9.65 | ||
| P/B | 1.3 | ||
| P/tB | 9.93 | ||
| EV/EBITDA | 7.13 |
EPS(TTM)14.39
EY10.37%
EPS(NY)13.29
Fwd EY9.58%
FCF(TTM)13.26
FCFY9.55%
OCF(TTM)14.38
OCFY10.36%
SpS58.99
BVpS106.71
TBVpS13.98
PEG (NY)N/A
PEG (5Y)N/A
Graham Number185.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.18 |
F-Score5
WACC8.33%
ROIC/WACC1.16
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.59%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.93%
Revenue Next 2Y-1.65%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year6.14%
EBIT Next 3Y0.99%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to IDP.DE.
What is the valuation status for IDP stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.
What is the financial health of BIOGEN INC (IDP.DE) stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.54% in the next year.